Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp

Summary

This is a pharmacokinetic evaluation of lactating women after receiving two doses of Ibrexafungerp. The study population included healthy lactating females who were at least 10 days postpartum with a fully established milk supply and were between the ages of 18 and 50 years at the time of screening

Timeline

Start

2023-07-12

Primary completion

2023-11-01

Completion

2023-11-01

Drugs

Indications